1. The Significance of Visenfree’s Approval
On September 22, 2025, Samchundang Pharmaceuticals announced that it had received approval from the Ministry of Food and Drug Safety (MFDS) in South Korea for its Eylea biosimilar, ‘Visenfree’ (SCD411), for the treatment of wet age-related macular degeneration (AMD). Both vial and pre-filled syringe (PFS) presentations were approved, enhancing patient convenience. This marks a significant milestone for the company’s entry into the domestic market and signals its readiness to compete in the rapidly growing AMD treatment landscape.
2. Analyzing the Impact on Fundamentals: Expecting Revenue Growth and Improved Profitability
This approval is expected to positively influence Samchundang Pharm.’s fundamentals.
- Revenue Growth and Market Share Expansion: The launch of Visenfree is projected to drive revenue growth and increase market share. The availability of the PFS presentation is expected to further enhance market competitiveness by improving patient convenience.
- Profitability Improvement: Sales of the high-value biosimilar are anticipated to contribute to improvements in operating and net profit margins.
- Validation of R&D Capabilities: The approval validates Samchundang Pharm.’s R&D capabilities and raises expectations for future pipeline development.
- Improved Cash Flow: Increased sales are expected to improve cash flow from operating activities, which can strengthen investments and financial stability.
3. Investment Strategies: Considering Growth Potential and Risk Factors
While this approval is likely to act as a positive catalyst for the stock price, investors should consider the following factors:
- Market Competition: The intensifying competition within the biosimilar market needs to be addressed strategically.
- Actual Sales Performance: It is crucial to monitor the actual sales figures and the pace of market penetration post-launch.
- Global Market Expansion: Closely observe the company’s progress in entering key international markets, such as the US and Europe.
FAQ
What is Visenfree?
Visenfree is a biosimilar of Eylea, developed by Samchundang Pharmaceuticals for the treatment of wet AMD.
What does this approval mean for Samchundang Pharmaceuticals?
It’s a crucial step for domestic market entry and is expected to contribute to increased sales and improved profitability.
What are the key factors to consider for investment?
Investors should consider the competitive landscape, actual sales performance, and the company’s progress in expanding to international markets.
Leave a Reply